Synthetic glucocorticoids are frequently used antenatally in order to reduce morbidity and mortality in babies born preterm and have been used in the management of fetuses known to be at risk of congenital adrenal hyperplasia. Although such treatment has short term advantages, evidence suggests that it can affect health in later life. Several studies have reported negative consequences of prenatal exposure to the synthetic glucocorticoid dexamethasone on offspring behavior in humans and in animal models, in association with changes in brain structure, hypothalamic-pituitary-adrenal axis function, neurotransmitter pathways, gene transcription and epigenetic regulation. These studies also highlight the importance of timing and tissue/organ-specific and sex-specific effects of prenatal glucocorticoid exposure. Here we review the evidence from human and animal studies that links prenatal synthetic glucocorticoid exposure with an increased risk for neurodevelopmental disorders.
Introduction
The concept of 'early life programming' is used to describe the association between environmental factors that occur during early life (pre-natal or postnatal) and an increased risk of diseases in later life [1] . According to this theory, environmental insults occurring at crucial developmental periods can permanently alter the physiology and function of developing organs, resulting in lifelong consequences for health [2] . Such developmental plasticity has been proposed to help the unborn animal to optimize its body systems for better survival in a predicted adverse postnatal environment, however if the expected environment does not match the real postnatal environment, it may lead to malfunction and disease [3] .
Physiological responses to environmental adversities are mediated by the hypothalamic-pituitary-adrenal (HPA) axis, which controls circulating glucocorticoid (GC) concentrations. Dysregulation of the HPA axis is associated with several neurodevelopmental disorders including autism [4] and schizophrenia [5] . Circulating GC levels are lower in the fetus compared to its mother as a consequence of the action of the enzyme 11b-hydroxysteroid dehydrogenase type 2 (11b-HSD2) at the fetoplacental barrier, which catalyses the conversion of active GC (e.g. cortisol in humans and corticosterone in rodents) into their inactive forms (cortisone and 11-dehydrocorticosterone), and thus protects the fetus. Nevertheless, this barrier is not complete, and high levels of maternal GC can overcome this enzymatic protection [6]; indeed, fetal exposure to elevated levels of maternal GC, as a consequence of maternal stress during pregnancy, may impact on the developing brain and result in permanent changes in brain function [7] .
In addition to exposure to increased endogenous GC levels following maternal stress, fetuses can also be exposed to high levels of synthetic GC (sGC), for example, dexamethasone (DEX) or betamethasone, which are frequently administered to mothers at risk of preterm delivery because of the clear benefits of GC on organ maturation, particularly the fetal lung [8] . sGC are additionally used in the management of fetuses at risk of (or diagnosed with) congenital adrenal hyperplasia to suppress fetal androgen production [9] . Such sGC are poor substrates for the 11b-HSD2 enzyme, and can readily cross the placental barrier. In this short review, we focus on the effects of prenatal sGC exposure on the brain, including effects on brain function and the epigenome.
Effects of prenatal glucocorticoid exposure on behavior
Although prenatal DEX exposure has been associated with a decrease in the rate of cerebral palsy in preterm infants [10] , it has also been associated with an increased risk of anxiety, hyperactivity and distractibility in preterm and term born children [10,11 ,12 ], with females being more susceptible to stress than males [11 ] . Nevertheless, reports on the outcomes of GC overexposure during early life are sometimes contradictory; for example, a long-term follow-up study of Swedish children who were prenatally treated with DEX showed no changes in psychopathology,
